Latest News and Press Releases

EDMONTON, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...

– PGX Technology further recognized as a disruptive technology – Additional support paves the way for the manufacturing of pharmaceutical-grade yeast beta glucan (YBG) EDMONTON, Alberta, Nov. 29,...

– Increased R&D activities focused on the completion of a clinical trial for oat beta glucan as a potential cholesterol reducer and on the development of yeast beta glucan as a potential inhalable...

EDMONTON, Alberta, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...

McMaster’s research team discovers new mechanism of action for PGX-YBG PGX-YBG demonstrates ability to reprogram macrophages on its own PGX-YBG may be a suitable therapeutic solution for patients...

EDMONTON, Alberta, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...

EDMONTON, Alberta, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...

– Company continues to increase R&D activities to advance clinical and preclinical programs – – Second quarter sales of $4,409,000 compared to $4,666,000 for second quarter 2020 – – Cash...

– Research focused on addressing root cause of disease and tissue damage for diseases such as COVID-19 – – Leveraging the unique expertise and methods developed by the Angiogenesis Foundation to...

- Second human trial to be conducted as part of a long-term Master Service Agreement with MHI- Phase 1 study with Ceapro’s pharmaceutical grade avenanthramide to be coordinated by MHI’s Montreal...